The Relamatrix Group was founded in 1993 on the premise
that the $1.5 trillion healthcare industry was ready for a new approach
to the process of finding, facilitating, following-up, and finalizing
With rapid commercialization of the healthcare industry along every step
of the patient care continuum, there has never been a greater need for
innovative ways to create deal opportunities for both established and
newly launched companies that provide products and services to the healthcare
New business can be developed many ways and relationships can be cultivated
through multiple channels. It is always more efficient, however, to work
through an existing relationship-to tap into the goodwill that exists
between two trusted colleagues- that allows one to quickly identify whether
a genuine business opportunity exists. This requires more than just "access"
to decision-makers, however. One needs "access" to an existing
relationship. This very observation served as the intellectual foundation
for the business model behind the Relamatrix Group.
We conceptualized a business development process based on the strength
of pre-existing relationships, not unlike the dynamics of lobbying and
public relations firms. Maximizing the collective goodwill of former senior
healthcare executives in the same way that former elected officials are
recruited to law firms and military personnel to lobbying organizations.
We recruit high-profile healthcare executives to serve as our Corporate
Ambassadors. Working through the powerful medium of personal relationships,
we are then able to eliminate courtesy meetings and ensure a more efficient
use of sales & marketing resources by gathering feedback directly
from the source in a professional and appropriate fashion.
In 1999, the Relamatrix Group globalized its client-base and operations,
launching its presence on the World Wide Web and implementing a public
relations program. The Relamatrix Group continues to expand its access
and influence through a culture of entrepreneurship and innovation. In
sum, we will continually stay on the leading edge of healthcare dealmaking
by representing the leading vendors in niche markets, assisting emerging
medical technologies become industry standards, and leveraging our resources
in return for equity in promising Internet ventures.